The COMPASS Trial | Zendy

Jan Steffel | Zendy; John W. Eikelboom | Zendy; Sonia S. Anand | Zendy; Olga Shestakovska | Zendy; Salim Yusuf | Zendy; Keith A.A. Fox | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The COMPASS Trial

Author(s) -

Jan Steffel,

John W. Eikelboom,

Sonia S. Anand,

Olga Shestakovska,

Salim Yusuf,

Keith A.A. Fox

Publication year - 2020

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.120.046048

Subject(s) - medicine , rivaroxaban , hazard ratio , stroke (engine) , myocardial infarction , aspirin , cohort , adverse effect , population , confidence interval , warfarin , surgery , atrial fibrillation , mechanical engineering , environmental health , engineering

Rivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) but increased the risk of major bleedings. Analysis of net clinical benefit (NCB) is of key clinical relevance and represents an integrated measure of overall patient outcome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research